Henagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor developed as an oral antihyperglycemic agent. SGLT2 is responsible for the majority of glucose reabsorption in the proximal renal tubules. By inhibiting this transporter, henagliflozin increases urinary glucose excretion and reduces blood glucose levels.
Henagliflozin has been investigated for the management of type 2 diabetes mellitus and related metabolic conditions.
Henagliflozin is a specialized small-molecule pharmaceutical API requiring controlled chemical synthesis, purification and comprehensive analytical characterization. API quality control focuses on identity, assay, related substances, residual solvents, water content and other physicochemical parameters.
CAS Number: 1326035-59-5
Molecular Formula: C24H23ClO6
Molecular Weight: 442.89 g/mol
Drug Class: SGLT2 Inhibitor
Therapeutic Class: Antidiabetic Agent
Therapeutic Area: Endocrinology / Metabolic Disorders
Henagliflozin selectively inhibits SGLT2, a transporter expressed mainly in the proximal renal tubules. Inhibition decreases renal glucose reabsorption and increases urinary glucose excretion.
This insulin-independent mechanism contributes to lowering plasma glucose concentrations.
Henagliflozin has been developed primarily for the treatment of:
Its clinical use and approved indications depend on the regulatory status and applicable product labeling in individual markets.
SGLT2 inhibition provides an insulin-independent pathway for glucose reduction. By promoting urinary glucose elimination, henagliflozin can improve glycemic control while its pharmacological class may also influence body weight and blood pressure through osmotic diuresis and natriuresis.
Henagliflozin is a synthetic, relatively lipophilic small molecule containing a chlorinated aromatic structure and multiple hydroxyl groups. It is generally handled as a crystalline pharmaceutical solid and has limited aqueous solubility.
Henagliflozin API quality evaluation may include:
Henagliflozin should be stored in a tightly closed container under controlled pharmaceutical conditions and protected from excessive heat, moisture and direct light. Exact storage requirements should follow validated stability data and the applicable product-specific specification.
Henagliflozin is relevant to pharmaceutical research involving SGLT2 inhibition, glucose reabsorption, renal glucose handling and type 2 diabetes management.
Henagliflozin is an oral SGLT2 inhibitor with CAS Number 1326035-59-5, molecular formula C24H23ClO6, and molecular weight 442.89 g/mol. Its mechanism is based on inhibition of renal glucose reabsorption, thereby increasing urinary glucose excretion and reducing blood glucose.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |